SODIUM PHOSPHATES IN PLASTIC CONTAINER
Clinical safety rating
cautionComprehensive clinical and safety monograph for SODIUM PHOSPHATES IN PLASTIC CONTAINER (SODIUM PHOSPHATES IN PLASTIC CONTAINER).
Sodium phosphates increase serum phosphate concentration, promoting renal excretion of calcium and phosphate, and inducing osmotic diarrhea to cleanse the colon.
| Metabolism | Not metabolized; renally excreted. |
| Excretion | Primarily renal (≥90% as inorganic phosphate and sodium). Fecal elimination is minimal (<5%) via unabsorbed phosphate. |
| Half-life | Terminal half-life of absorbed phosphate is approximately 0.5–1 hour in patients with normal renal function. Clinically, effects on serum phosphate are transient and depend on renal clearance. |
| Protein binding | Negligible (<1%); phosphate exists primarily as free anion. |
| Volume of Distribution | Approximately 0.2–0.3 L/kg, reflecting distribution primarily in extracellular fluid; does not extensively penetrate cells. |
| Bioavailability | Oral: approximately 30–50% (variable due to incomplete absorption and first-pass renal excretion). |
| Onset of Action | Oral: cathartic effect within 0.5–6 hours; intravenous: serum phosphate increase within minutes. |
| Duration of Action | Oral: catharsis lasting 1–3 hours. Intravenous: serum phosphate elevation lasts 1–2 hours post-infusion due to rapid renal elimination. |
| Molecular Weight | 163.94 (for Na3PO4·12H2O); 141.96 (for Na2HPO4); 119.98 (for NaH2PO4) |
Oral: 30-90 mL (equivalent to 3.75-11.25 g sodium phosphate) once daily, preferably in the morning, with a full glass of water. Dose may be increased up to 240 mL per day in divided doses. Rectal enema: 118 mL (monobasic sodium phosphate 19 g, dibasic sodium phosphate 7 g) as a single dose.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in patients with GFR < 30 mL/min/1.73 m2. For GFR 30-59 mL/min/1.73 m2, use with caution and reduce dose by 50%; monitor serum phosphate and electrolytes. Avoid in severe renal impairment. |
| Liver impairment | No specific dose adjustment for Child-Pugh class A, B, or C. Caution in ascites due to potential fluid shifts. Use lowest effective dose. |
| Pediatric use | Oral: For constipation, 2.5-10 mL (0.3-1.25 g) once daily for children 2-5 years; 10-20 mL (1.25-2.5 g) for 6-12 years; 20-40 mL (2.5-5 g) for 12 years and older. Rectal enema: 33-66 mL for children 5-11 years; 118 mL for ≥12 years. Dosing based on weight: 0.5-1 mL/kg per dose for oral solution, max 240 mL/day. |
| Geriatric use | Start at lower end of dosing range (30 mL oral once daily). Monitor renal function, electrolytes, and fluid balance. Avoid in elderly with reduced GFR. Increased risk of hyperphosphatemia and dehydration. |
| 1st trimester | Limited human data; use only if clearly needed. Intravenous phosphate solutions are generally avoided unless severe hypophosphatemia. |
| 2nd trimester | Limited human data; use only if clearly needed. Risk of hyperphosphatemia and hypocalcemia in mother and fetus. |
| 3rd trimester | Use caution; monitor serum phosphate and calcium. High doses may cause maternal hypocalcemia and tetany, potentially affecting fetal calcium homeostasis. |
Clinical note
Comprehensive clinical and safety monograph for SODIUM PHOSPHATES IN PLASTIC CONTAINER (SODIUM PHOSPHATES IN PLASTIC CONTAINER).
| Placental transfer | Phosphate ions cross the placenta by active transport. Fetal serum phosphate is higher than maternal. Excessive maternal phosphate may alter fetal calcium-phosphate balance. |
| Breastfeeding | Sodium phosphate is considered compatible with breastfeeding. Normal dietary phosphate is present in breast milk. High intravenous doses may transiently increase milk phosphate but are unlikely to harm infant. Monitor infant for signs of hyperphosphatemia if mother receives high doses. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Sodium phosphates are not associated with teratogenicity in animal studies. However, electrolyte imbalances (hypernatremia, hyperphosphatemia) secondary to excessive dosing could potentially affect fetal development indirectly. In the first trimester, avoid high doses due to theoretical risk of electrolyte disturbance affecting organogenesis. In second and third trimesters, use only if clearly needed and with monitoring of maternal electrolytes to prevent fetal acidosis or dehydration. |
| Fetal Monitoring | Monitor maternal serum electrolytes (sodium, phosphate, calcium, potassium), renal function, and acid-base status. In prolonged use or high doses, consider fetal heart rate monitoring and ultrasound for signs of fetal hydrops or electrolyte disturbances. Monitor for maternal signs of hypernatremia or hypocalcemia. |
| Fertility Effects | No known adverse effects on fertility in animal studies. High doses causing severe electrolyte disturbances could theoretically impair reproductive function, but at therapeutic doses no impact is expected. |
■ FDA Black Box Warning
Risk of acute phosphate nephropathy, including permanent renal impairment and need for dialysis, especially in patients with impaired renal function, dehydration, or those taking medications that affect renal function.
| Serious Effects |
HyperphosphatemiaHypocalcemiaRenal failure or severe renal impairmentDehydrationBowel obstruction or ileus (for oral formulations)
| Precautions | Avoid in patients with renal impairment, bowel obstruction, colitis, or dehydration; monitor electrolytes; risk of seizures due to electrolyte disturbances. |
| Food/Dietary | Avoid foods high in phosphorus (e.g., dairy, nuts, seeds, whole grains, cola) during treatment to prevent excessive phosphate levels. Coordinate with dietary restrictions based on renal function. |
| Clinical Pearls | Administer intravenously at a rate not exceeding 1 mmol/kg/h to avoid hypocalcemia. Monitor serum phosphate, calcium, and potassium closely during infusion. Avoid use in patients with hyperphosphatemia, hypocalcemia, or severe renal impairment (CrCl < 30 mL/min). Do not mix with calcium-containing solutions. May cause precipitation if infused with calcium or magnesium. |
| Patient Advice | This medication is used to increase phosphate levels in your blood. · Report any signs of low calcium such as muscle cramps, numbness, or tingling around the mouth. · Tell your healthcare provider if you have kidney problems or are on dialysis. · This medication is given as an infusion through a vein; you may feel warmth or pain at the injection site. · Avoid taking additional phosphate-containing supplements or laxatives without consulting your doctor. |
Loading safety data…